Program
trospium chloride
Also written as “Xanomeline/trospium chloride”, “Xanomeline/Trospium Chloride Capsule” and “Xanomeline/Trospium Chloride”.
Its studies are mostly in Schizophrenia · Urinary Bladder, Overactive · Alzheimer Disease · Mania · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Drug pageTrospium chloride: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 97 open or running | phase 4since Oct 13, 2025 | Jul 6, 2016 | Dec 3, 2026phase 1 · NCT07204418 |
| AbbVieits history only | 50 open or running | phase 4since Mar 16, 2009 | Mar 16, 2009 | none ahead |
| Keenova Therapeutics | 10 open or running | phase 2since Apr 24, 2007 | Apr 24, 2007 | none ahead |
Also a collaborator on its studies: Alkermes.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Keenova Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2007First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT00465959 · 24 enrolled · United States
TargetBeta
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
| trospiumrule | Bristol-Myers Squibb | phase 4 | 21 |
| Atropinerule | Laboratorios Sophia S.A de C.V. | phase 3 | 17 |
Studies
The one study Keenova Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00465959Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | Jun 2007 | 24 |
How it is read
Names in the registry
- “Xanomeline/trospium chloride”, 2 entries
- “Xanomeline/Trospium Chloride Capsule”, 2 entries
- “Xanomeline/Trospium Chloride”, 2 entries
- “Trospium Chloride”, 2 entries
- “trospium chloride”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 3 studies
- Urinary Bladder, Overactive, 3 studies
- Alzheimer Disease, 2 studies
- Mania, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.